The two studies came out of the UK's Tracking Cancer Evolution through Therapy (TRACERx) trial.
The GW Index outperformed the Dow Jones Industrial Average, the Nasdaq Composite, and the Nasdaq Biotech Index.
Natera discussed its plans to move into the whole-genome newborn screening market and provided updates on its NIPT and oncology businesses.
Natera saw total Q4 2016 revenues decline to $49.3 million, despite an increase in testing volumes.
The GenomeWeb Index rose more than 6 percent in January, outperforming the Dow, Nasdaq, and Nasdaq Biotechnology Index.
Going forward, Natera said it will market its Panorama NIPT assay and carrier screening test Horizon directly to physicians.
The investment bank set a price target of $18.00 for shares of the molecular diagnostics company.
The organization will promote public awareness of cfDNA-based NIPT, encourage legislation supporting testing, and push for reimbursement policy changes.
Natera alleges that Bio-Reference broke a contract by promoting a NIPS test based on Illumina technology over Panorama.
Natera will design a personalized liquid biopsy assay for each patient and will test its ability to monitor disease progression and treatment response.
The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.
There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.
The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.
In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.